

References

Ablefoni, K., Buchholz, A., Ueberham, L., Hilbert, S., Dages, N., & Husser, D. *et al.* (2019). Initial rivaroxaban dosing in patients with atrial fibrillation. *Clinical Cardiology*, 42(10), 873-880. doi: 10.1002/clc.23235

About FHS | Framingham Heart Study. (2020). Retrieved 27 September 2020, from <https://framinghamheartstudy.org/fhs-about/>

Akwaa, F., & Spyropoulos, A. (2013). Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations. *Hospital Practice*, 41(1), 8-18. doi: 10.3810/hp.2013.02.1008

Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013). Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. *Current Emergency And Hospital Medicine Reports*, 1(2), 83-97. doi: 10.1007/s40138-013-0014-6

Ashok, P., & Subramanian, V. (2017). Importance of Drug Utilization Evaluation Studies In Patient Health Care. *Indian Journal Of Pharmacy Practice*, 10(3), 157-159. doi: 10.5530/ijopp.10.3.34

Bikdeli, B., Gupta, A., Mody, P., Lampropulos, J., & Dharmarajan, K. (2012). Most Important Outcomes Research Papers on Anticoagulation for Cardiovascular Disease. *Circulation: Cardiovascular Quality And Outcomes*, 5(5). doi: 10.1161/circoutcomes.112.968701

Branch, K., Probstfield, J., Eikelboom, J., Bosch, J., Maggioni, A., & Cheng, R. *et al.* (2019). Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic

Coronary or Peripheral Artery Disease. *Circulation*, 140(7), 529-537. doi: 10.1161/circulationaha.119.039609

Chen, S., & Patel, M. (2018). Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. *Progress In Cardiovascular Diseases*, 60(4-5), 514-523. doi: 10.1016/j.pcad.2018.01.005

Cheung, K., Teichert, M., Moll, H., Stricker, B., & Visser, L. (2018). Filled prescriptions of age-related contraindicated drugs in children: a one-year nationwide cohort study in the Netherlands. *International Journal Of Clinical Pharmacy*, 40(5), 1137-1143. doi: 10.1007/s11096-018-0717-6

Chung, M., Refaat, M., Shen, W., Kutuyifa, V., Cha, Y., & Di Biase, L. *et al.* (2020). Atrial Fibrillation. *Journal Of The American College Of Cardiology*, 75(14), 1689-1713. doi: 10.1016/j.jacc.2020.02.025

Cushman, M. (2007). Epidemiology and Risk Factors for Venous Thrombosis. *Seminars In Hematology*, 44(2), 62-69. doi: 10.1053/j.seminhematol.2007.02.004

Farooqui, R., Hoor, T., Karim, N., & Muneer, M. (2018). Potential Drug-Drug Interactions among patient's prescriptions collected from Medicine out-patient setting. *Pakistan Journal Of Medical Sciences*, 34(1). doi: 10.12669/pjms.341.13986

Food Drug Administration. (2011). Indication of Rivaroxaban. Retrieved 12 Sept 2020, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf

Harter, K., Levine, M., & Henderson, S. (2015). Anticoagulation Drug Therapy: A Review. *Western Journal Of Emergency Medicine*, 16(1), 11-17. doi: 10.5811/westjem.2014.12.22933

Iwasaki, Y., Nishida, K., Kato, T., & Nattel, S. (2011). Atrial Fibrillation Pathophysiology. *Circulation*, 124(20), 2264-2274. doi: 10.1161/circulationaha.111.019893

Jiang, X., Samant, S., Lesko, L., & Schmidt, S. (2015). Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. *Clinical Pharmacokinetics*, 54(2), 147-166. doi: 10.1007/s40262-014-0230-6

Johnson, J. (2012). Warfarin Pharmacogenetics. *Circulation*, 125(16), 1964-1966. doi: 10.1161/circulationaha.112.100628

Ko, D., Rahman, F., Schnabel, R., Yin, X., Benjamin, E., & Christophersen, I. (2016). Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. *Nature Reviews Cardiology*, 13(6), 321-332. doi: 10.1038/nrcardio.2016.45

Letsas, K., Karamichalakis, N., Vlachos, K., Georgopoulos, S., Bakalakos, A., Efremidis, M., & Sideris, A. (2015). Managing atrial fibrillation in the very elderly patient: challenges and solutions. *Vascular Health And Risk Management*, 555. doi: 10.2147/vhrm.s83664

Mackman, N., Tilley, R., & Key, N. (2007). Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. *Arteriosclerosis, Thrombosis, And Vascular Biology*, 27(8), 1687-1693. doi: 10.1161/atvbaha.107.141911

Magnussen, C., Niiranen, T., Ojeda, F., Gianfagna, F., Blankenberg, S., & Njølstad, I. *et al.* (2017). Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts. *Circulation*, 1. doi: 10.1161/circulationaha.117.028981

Manning, W., Singer, D., & Lip, G. (2020). Atrial fibrillation: Anticoagulant therapy to prevent thromboembolism.

Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. (2017). What is polypharmacy? A systematic review of definitions. *BMC Geriatrics*, 17(1). doi: 10.1186/s12877-017-0621-2

Markides, V. (2003). Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. *Heart*, 89(8), 939-943. doi: 10.1136/heart.89.8.939

Meena, D., & Jayanthi, M. (2019). Drug utilization research: a review. *International Journal Of Basic & Clinical Pharmacology*, 8(2), 354. doi: 10.18203/2319-2003.ijbcp20190161

Myers, K., & Lyden, A. (2019). A Review on the New and Old Anticoagulants. *Orthopaedic Nursing*, 38(1), 43-52. doi: 10.1097/nor.0000000000000517

Naser, N., Dilic, M., Durak, A., Kulic, M., Pepic, E., Smajic, E., & Kusljugic, Z. (2017). The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation. *Materia Socio Medica*, 29(4), 231. doi: 10.5455/msm.2017.29.231-236

Oh, S., Kim, K., Ahn, H., Cho, H., & Choi, Y. (2010). Remodeling of Ion Channel Expression in Patients with Chronic Atrial Fibrillation and Mitral Valvular Heart Disease. *The Korean Journal Of Internal Medicine*, 25(4), 377. doi: 10.3904/kjim.2010.25.4.377

O'Leary, G. M. (2017). *A review of novel oral anticoagulants. Nursing Critical Care, 12(3), 32–39.* doi:10.1097/01.ccn.0000511829.26969.85

Patel, P., Pandya, J., & Goldberg, M. (2017). NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation. *Cureus.* doi: 10.7759/cureus.1395

Pothineni, N., & Vallurupalli, S. (2018). Gender and AF: Differences and Disparities. *US Cardiology Review, 12(2), 103.* doi: 10.15420/usc.2017:39:1

Samama, M. (2011). The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. *Thrombosis Research, 127(6), 497-504.* doi: 10.1016/j.thromres.2010.09.008

Shah, S., Luu, S., Caestino, M., David, J., & Christopher, B. (2018). Management of atrial fibrillation-flutter: uptodate guideline paper on the current evidence. *Journal Of Community Hospital Internal Medicine Perspectives, 8(5), 269-275.* doi: 10.1080/20009666.2018.1514932

Singh, R., & Emmady, P. (2020). *Rivaroxaban.* StatPearls Publishing.

Trujillo, T., & Dobesh, P. (2014). Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications. *Drugs, 74(14), 1587-1603.* doi: 10.1007/s40265-014-0278-5

Vene, N., & Mavri, A. (2020). An Overview of the Anticoagulant Drugs Used in Routine Clinical Practice. Retrieved 27 September 2020

Wanat, M. (2013). Novel Oral Anticoagulants: A Review of New Agents. *Postgraduate Medicine, 125(4), 103-114.* doi: 10.3810/pgm.2013.07.2683

Wettermark, B., Elseviers, M., Almarsdóttir, A., Andersen, M., Benko, R., & Bennie, M. *et al.* (2016). Introduction to drug utilization research. *Drug Utilization Research*, 1-12. doi: 10.1002/9781118949740.ch1

Wetterneck, T., Walker, J., Blosky, M., Cartmill, R., Hoonakker, P., & Johnson, M. *et al.* (2011). Factors contributing to an increase in duplicate medication order errors after CPOE implementation. *Journal Of The American Medical Informatics Association*, 18(6), 774-782. doi: 10.1136/amiajnl-2011-000255

World Health Organization. (2020). The ATC/DDD Methodology. Retrieved 11 May 2020, from https://www.who.int/medicines/regulation/medicines-safety/toolkit_methodology/en/

Xu, J., Luc, J., & Phan, K. (2016). Atrial fibrillation: review of current treatment strategies. *Journal Of Thoracic Disease*, 8(9), E886-E900. doi: 10.21037/jtd.2016.09.13